HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases

ACS Chemical Biology

Volumn 11, Issue 4, 2016, Pages 1074-1081

  Zhao, Xue Zhi ^a   Smith, Steven J ^b   Maskell, Daniel P ^d   Metifiot, Mathieu ^c   Pye, Valerie E ^d   Fesen, Katherine ^c   Marchand, Christophe ^c   Pommier, Yves ^c   Cherepanov, Peter ^d,e   Hughes, Stephen H ^c   Burke, Terrence R ^a  

^a Chemical Biology Laboratory   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; VIRUS DNA; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; EC50; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SPUMAVIRUS; VIRUS RESISTANCE; CHEMISTRY; METABOLISM; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS;

EID: 84966393393     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00948     Document Type: Article

References (43)

1. Pommier, Y. and Marchand, C. (2012) Interfacial inhibitors: Targeting macromolecular complexes Nat. Rev. Drug Discovery 11, 25-36 10.1038/nrd3404
2. Cherepanov, P., Maertens, G. N., and Hare, S. (2011) Structural insights into the retroviral DNA integration apparatus Curr. Opin. Struct. Biol. 21, 249-256 10.1016/j.sbi.2010.12.005
3. Di Santo, R. (2014) Inhibiting the HIV integration process: Past, present, and the future J. Med. Chem. 57, 539-566 10.1021/jm400674a
4. Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G., and Hughes, S. H. (2010) Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication J. Virol. 84, 9864-9878 10.1128/JVI.00915-10
5. Cuevas, J. M., Geller, R., Garijo, R., Lopez-Aldeguer, J., and Sanjuan, R. (2015) Extremely high mutation rate of HIV-1 in vivo PLoS Biol. 13, e1002251 10.1371/journal.pbio.1002251
6. Wainberg, M. A., Zaharatos, G. J., and Brenner, B. G. (2011) Development of antiretroviral drug resistance N. Engl. J. Med. 365, 637-646 10.1056/NEJMra1004180
7. Garrido, C., Villacian, J., Zahonero, N., Pattery, T., Garcia, F., Gutierrez, F., Caballero, E., Van Houtte, M., Soriano, V., and de Mendoza, C. (2012) Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens Antimicrob. Agents Chemother. 56, 2873-2878 10.1128/AAC.06170-11
8. Geretti, A. M., Armenia, D., and Ceccherini-Silberstein, F. (2012) Emerging patterns and implications of HIV-1 integrase inhibitor resistance Curr. Opin. Infect. Dis. 25, 677-686 10.1097/QCO.0b013e32835a1de7
9. Quashie, P. K., Mesplede, T., and Wainberg, M. A. (2013) Evolution of HIV integrase resistance mutations Curr. Opin. Infect. Dis. 26, 43-49 10.1097/QCO.0b013e32835ba81c
10. Ballantyne, A. D. and Perry, C. M. (2013) Dolutegravir: First global approval Drugs 73, 1627-1637 10.1007/s40265-013-0121-4
11. Hurt, C. B., Sebastian, J., Hicks, C. B., and Eron, J. J. (2014) Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012 Clin. Infect. Dis. 58, 423-431 10.1093/cid/cit697
12. McCormack, P. L. (2014) Dolutegravir: A review of its use in the management of HIV-1 infection in adolescents and adults Drugs 74, 1241-1254 10.1007/s40265-014-0256-y
13. Mesplede, T., Quashie, P. K., and Wainberg, M. A. (2012) Resistance to HIV integrase inhibitors Curr. Opin. HIV AIDS 7, 401-408 10.1097/COH.0b013e328356db89
14. Wainberg, M. A., Mesplede, T., and Raffi, F. (2013) What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med. 11, 249 10.1186/1741-7015-11-249
15. Shah, B. M., Schafer, J. J., and DeSimone, J. A., Jr. (2014) Dolutegravir: A new integrase strand transfer inhibitor for the treatment of HIV Pharmacotherapy 34, 506-520 10.1002/phar.1386
16. Malet, I., Gimferrer Arriaga, L., Artese, A., Costa, G., Parrotta, L., Alcaro, S., Delelis, O., Tmeizeh, A., Katlama, C., Valantin, M.-A., Ceccherini-Silberstein, F., Calvez, V., and Marcelin, A.-G. (2014) New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors J. Antimicrob. Chemother. 69, 2118-2122 10.1093/jac/dku095
17. de Souza Cavalcanti, J., de Paula Ferreira, J. L., Morenade Souza Guimaraes, P., Vidal, J. E., and de Macedo Brigido, L. F. (2015) High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen J. Antimicrob. Chemother. 70, 926-929 10.1093/jac/dku439
18. Hare, S., Gupta, S., Valkov, E., Engelman, A., and Cherepanov, P. (2010) Retroviral intasome assembly and inhibition of DNA strand transfer Nature 464, 232-236 10.1038/nature08784
19. Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., and Cherepanov, P. (2010) Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance Proc. Natl. Acad. Sci. U. S. A. 107, 20057-20062 10.1073/pnas.1010246107
20. Hare, S., Smith, S. J., Metifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., and Cherepanov, P. (2011) Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) Mol. Pharmacol. 80, 565-572 10.1124/mol.111.073189
21. Menendez-Arias, L. (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments Antiviral Res. 98, 93-120 10.1016/j.antiviral.2013.01.007
22. Serrao, E., Odde, S., Ramkumar, K., and Neamati, N. (2009) Raltegravir, elvitegravir, and metoogravir: The birth of "me-too" HIV-1 integrase inhibitors Retrovirology 6, 25 10.1186/1742-4690-6-25
23. Zhao, X. Z., Smith, S. J., Metifiot, M., Johnson, B. C., Marchand, C., Pommier, Y., Hughes, S. H., and Burke, T. R., Jr. (2014) Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants J. Med. Chem. 57, 1573-1582 10.1021/jm401902n
24. Zhao, X. Z., Smith, S. J., Metifiot, M., Marchand, C., Boyer, P. L., Pommier, Y., Hughes, S. H., and Burke, T. R., Jr. (2014) 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1 J. Med. Chem. 57, 5190-5202 10.1021/jm5001908
25. Hare, S., Maertens, G. N., and Cherepanov, P. (2012) 3′-Processing and strand transfer catalysed by retroviral integrase in crystallo EMBO J. 31, 3020-3028 10.1038/emboj.2012.118
26. Johns, B. A., Kawasuji, T., and Velthuisen, E. J. (2013) HIV integrase inhibitors RSC Drug Discovery Ser. 32, 149-188 10.1039/9781849737814-00149
27. Charpentier, C., Karmochkine, M., Laureillard, D., Tisserand, P., Belec, L., Weiss, L., Si-Mohamed, A., and Piketty, C. (2008) Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy HIV Med. 9, 765-770 10.1111/j.1468-1293.2008.00628.x
28. Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Teppler, H., and Nguyen, B.-Y. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection N. Engl. J. Med. 359, 355-365 10.1056/NEJMoa0708978
29. Kawasuji, T., Johns, B. A., Yoshida, H., Weatherhead, J. G., Akiyama, T., Taishi, T., Taoda, Y., Mikamiyama-Iwata, M., Murai, H., Kiyama, R., Fuji, M., Tanimoto, N., Yoshinaga, T., Seki, T., Kobayashi, M., Sato, A., Garvey, E. P., and Fujiwara, T. (2013) Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles J. Med. Chem. 56, 1124-1135 10.1021/jm301550c
30. Johns, B. A., Kawasuji, T., Weatherhead, J. G., Taishi, T., Temelkoff, D. P., Yoshida, H., Akiyama, T., Taoda, Y., Murai, H., Kiyama, R., Fuji, M., Tanimoto, N., Jeffrey, J., Foster, S. A., Yoshinaga, T., Seki, T., Kobayashi, M., Sato, A., Johnson, M. N., Garvey, E. P., and Fujiwara, T. (2013) Carbamoyl pyridone HIV-1 integrase Inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSKi349572) and (S/GSK1265744) J. Med. Chem. 56, 5901-5916 10.1021/jm400645w
31. Raheem, I. T., Walji, A. M., Klein, D., Sanders, J. M., Powell, D. A., Abeywickrema, P., Barbe, G., Bennet, A., Clas, S. D., Dubost, D., Embrey, M., Grobler, J., Hafey, M. J., Hartingh, T. J., Hazuda, D. J., Miller, M. D., Moore, K. P., Pajkovic, N., Patel, S., Rada, V., Rearden, P., Schreier, J. D., Sisko, J., Steele, T. G., Truchon, J. F., Wai, J., Xu, M., and Coleman, P. J. (2015) Discovery of 2-pyridinone aminals: A prodrug strategy to advance a second generation of HIV-1 Integrase strand transfer inhibitors J. Med. Chem. 58, 8154-8165 10.1021/acs.jmedchem.5b01037
32. Metifiot, M., Vandegraaff, N., Maddali, K., Naumova, A., Zhang, X., Rhodes, D., Marchand, C., and Pommier, Y. (2011) Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143 AIDS 25, 1175-1178 10.1097/QAD.0b013e3283473599
33. Shen, Y., Altman, M. D., Ali, A., Nalam, M. N. L., Cao, H., Rana, T. M., Schiffer, C. A., and Tidor, B. (2013) Testing the substrate-envelope hypothesis with designed pairs of compounds ACS Chem. Biol. 8, 2433-2441 10.1021/cb400468c
34. Nicholls, A., McGaughey, G. B., Sheridan, R. P., Good, A. C., Warren, G., Mathieu, M., Muchmore, S. W., Brown, S. P., Grant, J. A., Haigh, J. A., Nevins, N., Jain, A. N., and Kelley, B. (2010) Molecular shape and medicinal chemistry: A perspective J. Med. Chem. 53, 3862-3886 10.1021/jm900818s
35. Metifiot, M., Maddali, K., Johnson, B. C., Hare, S., Smith, S. J., Zhao, X. Z., Marchand, C., Burke, T. R., Jr., Hughes, S. H., Cherepanov, P., and Pommier, Y. (2013) Activities, crystal structures and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase ACS Chem. Biol. 8, 209-217 10.1021/cb300471n
36. Zhao, X. Z., Maddali, K., Metifiot, M., Smith, S. J., Vu, B. C., Marchand, C., Hughes, S. H., Pommier, Y., and Burke, T. R., Jr. (2012) Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors Chem. Biol. Drug Des. 79, 157-165 10.1111/j.1747-0285.2011.01270.x
37. Brachmann, A., Koenig, J., Julius, C., and Feldbruegge, M. (2004) A reverse genetic approach for generating gene replacement mutants in Ustilago maydis Mol. Genet. Genomics 272, 216-226 10.1007/s00438-004-1047-z
38. Kabsch, W. (2010) Xds Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 125-132 10.1107/S0907444909047337
39. Evans, P. (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics Acta Crystallogr., Sect. D: Biol. Crystallogr. 67, 282-292 10.1107/S090744491003982X
40. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132 10.1107/S0907444904019158
41. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Echols, N., Headd, J. J., Hung, L.-W., Jain, S., Kapral, G. J., Grosse Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2011) The Phenix software for automated determination of macromolecular structures Methods 55, 94-106 10.1016/j.ymeth.2011.07.005
42. Chen, V. B., Arendall, W. B., III, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: All-atom structure validation for macromolecular crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 12-21 10.1107/S0907444909042073
43. Zhao, X. Z., Semenova, E. A., Vu, B. C., Maddali, K., Marchand, C., Hughes, S. H., Pommier, Y., and Burke, T. R. (2008) 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-Based HIV-1 Integrase Inhibitors J. Med. Chem. 51, 251-259 10.1021/jm070715d